01
Clinical
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data Randomization to be Completed in Phase II Part in Q4 2025 - Yahoo Finance
Transgene reported positive randomized Phase I data for its individualized neoantigen therapeutic cancer vaccine, TG4050. The company plans to complete randomization for the Phase II part of the trial in Q4 2025, marking a key milestone in the program's clinical progression.